英文 – YC Biotech

Taiwanese Teams Advance to FDA: YC Biotech and JY Biomed Submit Pre-IND Meeting Application for ExoVeris™ Exosome Therapy

Taipei, Taiwan | September 18, 2025 Taiwanese biotech teams continue to strengthen their presence in the international regenerative medicine arena. YC Biotech Co., Ltd. and JY Biomed Co., Ltd. recently submitted a Pre-Investigational New Drug (Pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) for ExoVeris™, advancing the product toward clinical development. ExoVeris™ […]

Taiwanese Teams Advance to FDA: YC Biotech and JY Biomed Submit Pre-IND Meeting Application for ExoVeris™ Exosome Therapy Read More »

YC Biotech and JY Biomed Join Forces to Launch a New Stage of Stemis™ Clinical Development — Submission of FDA Pre-IND Meeting Application

YC Biotech and Taipei Medical University Hospital Launch Alzheimer’s Stem Cell Clinical Trial

YC Biotech and JY BioMed Partner to Usher in New Anti-Aging Era: Stem Cell Clinical Trial Underway

YC Biotech Partners with Neogence Group’s Getraising Biotechnology to Enter the Beauty and Skincare Market

Leave a Comment / 英文, News_en / yc89192889

Taipei City – April 12, 2023 YC Biotech, a global leader in advanced biotechnology research and development, has officially partnered with Getraising Biotechnology, a premier cosmetics and skincare OEM manufacturer under the Neogence Group. The two companies have formalized their collaboration by signing a memorandum of cooperation, marking the beginning of a long-term strategic alliance.

YC Biotech Partners with Neogence Group’s Getraising Biotechnology to Enter the Beauty and Skincare Market Read More »

英文

Taiwanese Teams Advance to FDA: YC Biotech and JY Biomed Submit Pre-IND Meeting Application for ExoVeris™ Exosome Therapy

YC Biotech and JY Biomed Join Forces to Launch a New Stage of Stemis™ Clinical Development — Submission of FDA Pre-IND Meeting Application

YC Biotech and Taipei Medical University Hospital Launch Alzheimer’s Stem Cell Clinical Trial

YC Biotech and JY BioMed Partner to Usher in New Anti-Aging Era: Stem Cell Clinical Trial Underway

YC Biotech Partners with Neogence Group’s Getraising Biotechnology to Enter the Beauty and Skincare Market

🔸Contains fully absorbable nanomolecular exosomes (stem cell grade)

🔸Provides deep tissue regeneration and revitalization

🔸Incorporates a curated assortment of tripeptides and tetrapeptides to effectively combat wrinkles, dry skin, and inflammation

🔸Utilizes high molecular weight hyaluronic acid for prolonged hydration

🔸Enriched with hydrolyzed marine collagen to enhance skin firmness and elasticity

🔸Completely absorbable stem cell grade nanomolecular exosomes

🔸An elixir for rapid restoration of skin

🔸A soothing, moisture retaining, anti-aging concoction

🔸Contains fully absorbable nanomolecular exosomes (stem cell grade)

🔸Provides deep tissue regeneration and revitalization

🔸Incorporates a curated assortment of tripeptide & tetrapeptides to effectively combat wrinkling, dry skin and inflammation

The complexity and demands of protocols have increased in recent years.

That complexity is putting a burden on patients and investigators alike and can heavily impact patient enrollment rates.

Yet amending protocols mid-stream will noticeably increase the time and cost of the development program with no guarantee of outcome improvement.

All stages of the drug development life cycle, after drug discovery involve CMC.

After clinical trials the scale-up process must ensure that the larger batches of product are the same and meet the same specifications as the drug tested in the clinical trials, and after the manufacturing process is qualified, lot release and in-process testing will continue to take place.

試驗計劃的複雜性和要求近年來不斷增加，使受試者和研究人員帶來了負擔，也可能影響受試者的參與率。然而，中途修改試驗計劃將增加開發計劃的時間和成本，並不能保證結果的改善。

透過我們的專業支持，客戶可以確保其藥物開發過程順利進行，並符合相關的法規和品質標準，從而實現成功的藥物上市。

PK樣本分析

快速PK篩選

ELISA 測試

最佳給藥方案分析